Silexion Therapeutics Corp Warrant (SLXNW) Stock Price
SLXNWStock
$0.01
Market Cap—
P/E—
PEG Ratio—
Div yield—
Beta-1.06
SLXNW Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-48.87%
Price vs S&P 500 (4W)-71.43%
VGM Score14.66
Industry Peers — Biological Products(183)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
SLXNWSilexion Therapeutics Corp Warrant | — | — | F | $0.01 |
| AMGNAmgen Inc | C | C | B | $432.42 |
| GILDGilead Sciences Inc | C | B | B | $145.68 |
| ARGXargenx SE American Depositary Shares | D | A | B | $1023.21 |
| MRNAModerna, Inc. Common Stock | D | C | A | $137.99 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | A | $207.88 |
| BIIBBiogen Inc. Common Stock | C | D | B | $218.50 |
| BNTXBioNTech SE American Depositary Share | C | C | C | $102.08 |
| NBIXNeurocrine Biosciences Inc | C | B | C | $154.06 |
| EXELExelixis Inc | C | B | B | $54.45 |
| HALOHalozyme Therapeutics, Inc. | C | B | B | $105.35 |
About Silexion Therapeutics Corp Warrant
Silexion Therapeutics is a clinical-stage biotechnology company focused on developing treatments for KRAS-driven cancers. Its lead candidate, SIL204, is a locally administered RNA interference therapy targeting locally advanced pancreatic cancer patients with specific KRAS mutations (G12D/G12V), used in combination with standard chemotherapy. The therapy addresses non-resectable tumors that cannot be surgically removed, representing a significant unmet medical need.